Cargando…

Prostaglandin E2 receptor 3 (EP3) signaling promotes migration of cervical cancer via urokinase-type plasminogen activator receptor (uPAR)

PURPOSE: Cervical cancer metastasis results in poor prognosis and increased mortality, which is not separated from inflammatory reactions accumulated by prostaglandin E2 (PGE2). As a specific G-protein coupled PGE2 receptor, EP3 is demonstrated as a negative prognosticator of cervical malignancy. No...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Yao, Peng, Lin, Vattai, Aurelia, Deuster, Eileen, Kuhn, Christina, Dannecker, Christian, Mahner, Sven, Jeschke, Udo, von Schönfeldt, Viktoria, Heidegger, Helene H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article – Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382663/ https://www.ncbi.nlm.nih.gov/pubmed/32488496 http://dx.doi.org/10.1007/s00432-020-03272-0

Ejemplares similares

The Prostaglandin EP3 Receptor Is an Independent Negative Prognostic Factor for Cervical Cancer Patients
por: Heidegger, Helene, et al.
Publicado: (2017)

Prostaglandin E2 receptor EP1 expression in vulvar cancer
por: Buchholz, Anna, et al.
Publicado: (2022)

The prostaglandin receptor EP2 determines prognosis in EP3-negative and galectin-3-high cervical cancer cases
por: Dietlmeier, Sebastian, et al.
Publicado: (2020)

Prostaglandin E(2) receptor 3 signaling is induced in placentas with unexplained recurrent pregnancy losses
por: Ye, Yao, et al.
Publicado: (2018)

Prostaglandin receptor EP3 regulates cell proliferation and migration with impact on survival of endometrial cancer patients
por: Zhu, Junyan, et al.
Publicado: (2017)

Role of Plasminogen Activator Inhibitor Type 1 in Pathologies of Female Reproductive Diseases
por: Ye, Yao, et al.
Publicado: (2017)

Urokinase Plasminogen Activator Receptor (uPAR) Targeted Nuclear Imaging and Radionuclide Therapy
por: Li, Dan, et al.
Publicado: (2013)

Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer
por: Zhai, Bing-Tao, et al.
Publicado: (2022)

Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer
por: Montuori, Nunzia, et al.
Publicado: (2016)

EP4 as a Negative Prognostic Factor in Patients with Vulvar Cancer
por: Buchholz, Anna, et al.
Publicado: (2021)

Tumour Microenvironments Induce Expression of Urokinase Plasminogen Activator Receptor (uPAR) and Concomitant Activation of Gelatinolytic Enzymes
por: Magnussen, Synnøve, et al.
Publicado: (2014)

Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) promote neurorepair in the ischemic brain
por: Merino, Paola, et al.
Publicado: (2017)

Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors
por: Mauro, Concetta Di, et al.
Publicado: (2017)

The Urokinase Receptor (uPAR) Facilitates Clearance of Borrelia burgdorferi
por: Hovius, Joppe W. R., et al.
Publicado: (2009)

Expression of Progesterone Receptor A as an Independent Negative Prognosticator for Cervical Cancer
por: Garrido, Fabian, et al.
Publicado: (2023)

The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style
por: Margheri, Francesca, et al.
Publicado: (2014)

Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications
por: Persson, Morten, et al.
Publicado: (2013)

PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectives
por: Skovgaard, Dorthe, et al.
Publicado: (2016)

Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer
por: Illemann, Martin, et al.
Publicado: (2014)

Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography
por: Zhao, Baoyu, et al.
Publicado: (2015)

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
por: Mahmood, Niaz, et al.
Publicado: (2018)

Data on the regulation of moesin and merlin by the urokinase receptor (uPAR): Model explaining distal activation of integrins by uPAR
por: Degryse, Bernard, et al.
Publicado: (2017)

Urokinase Receptor uPAR Downregulation in Neuroblastoma Leads to Dormancy, Chemoresistance and Metastasis
por: Shmakova, Anna A., et al.
Publicado: (2022)

Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours
por: Witte, J H de, et al.
Publicado: (2001)

Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic Intervention
por: Leth, Julie Maja, et al.
Publicado: (2021)

Urokinase-type plasminogen activator receptor (uPAR) assessed by liquid biopsies and PET/CT for prognostication in head and neck cancer patients
por: Risør, Louise Madeleine, et al.
Publicado: (2022)

Urokinase-Type Plasminogen Activator Receptor (uPAR) Cooperates with Mutated KRAS in Regulating Cellular Plasticity and Gemcitabine Response in Pancreatic Adenocarcinomas
por: Peng, Luogen, et al.
Publicado: (2023)

Prostaglandin E2 Receptor 4 (EP4) Affects Trophoblast Functions via Activating the cAMP-PKA-pCREB Signaling Pathway at the Maternal-Fetal Interface in Unexplained Recurrent Miscarriage
por: Peng, Lin, et al.
Publicado: (2021)

Nuclear receptor corepressor (NCoR) is a positive prognosticator for cervical cancer
por: Beilner, Daniel, et al.
Publicado: (2021)

Urokinase Plasminogen Activator Receptor (uPAR) and Plasminogen Activator Inhibitor-1 (PAI-1) Are Potential Predictive Biomarkers in Early Stage Oral Squamous Cell Carcinomas (OSCC)
por: Magnussen, Synnøve, et al.
Publicado: (2014)

Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group
por: Sorio, Claudio, et al.
Publicado: (2011)

Author Correction: Urokinase-type plasminogen activator receptor (uPAR) assessed by liquid biopsies and PET/CT for prognostication in head and neck cancer patients
por: Risør, Louise Madeleine, et al.
Publicado: (2023)

EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer
por: Semmlinger, Anna, et al.
Publicado: (2018)

The Urokinase Receptor (uPAR) as a “Trojan Horse” in Targeted Cancer Therapy: Challenges and Opportunities
por: Metrangolo, Virginia, et al.
Publicado: (2021)

A doxycycline-inducible urokinase receptor (uPAR) upregulates uPAR activities including resistance to anoikis in human prostate cancer cell lines
por: Hasanuzzaman, Mohammad, et al.
Publicado: (2007)

Regulatory T Cells with Additional COX-2 Expression Are Independent Negative Prognosticators for Vulvar Cancer Patients
por: Ansorge, Nadine, et al.
Publicado: (2022)

Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer
por: Christensen, Anders, et al.
Publicado: (2017)

Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis
por: Garnæs, Emilie, et al.
Publicado: (2019)

The superoxide scavenger TEMPOL induces urokinase receptor (uPAR) expression in human prostate cancer cells
por: Lejeune, Danielle, et al.
Publicado: (2006)

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors
por: Oh, Felix, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jpefi2k2diqbsctmj97jqtqve4